Antihypertensive treatment in the prevention of atherosclerosis in diabetic patients

Česká verzia

Authors: Ján Murín
Authors place of work: I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava
Published in the journal: Forum Diab 2021; 10(Supplementum 1): 37-40
Category:

Summary

Hypertension is the main risk factor (RF) for the development of ischemic heart disease (about 50%), heart failure, cerebrovascular (about 60%) and peripheral arterial disease, kidney failure, atrial fibrillation and all-cause mortality. Also diabetes (T2D) is an important RF for the development of cardiovascular (CV) disease and most patients suffer also from severe and resistant hypertension. Atherosclerotic vascular disease in T2D is about 2–4 times more frequent: due to hyperglycemia, AGEs and insulin resistance, due to vascular inflammation, but also due to hypertension supporting endotelial dysfunction and structural and functional changes of vascular matrix. Intensive antihypertensive treatment reduces the occurrence of major CV events: stroke, myocardial infarction and heart failure. In T2D we start with the antagonists of RAAS (HOPE and EUROPA studies), but due to severe or resistant hypertension present often in these patients we usually add-on also thiazide and calcium channel blockers (dihydropyridines). If we need still to add antihypertensive, it usually is spironolactone. Beta-blockers are used only if there is also another indication: arrhythmias, heart failure or recent acute myocardial infarction.

Keywords:

atherosclerotic vascular disease – cardiovascular events – diabetes mellitus type 2 – hypertension

Zdroje

Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2095–2128. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)61728–0>.
Institute for Health Metrics and Evaluation. GBD Compare, Seattle, University of Washington. 2015. Informácie dostupné z WWW: <http://healthdata.org>.
Danaei G, Finucane MM, Lin JK et al. National, regional and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants Lancet 2011; 377(9765): 568–577. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)62036–3>.
Mozaffarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics – 2016 update: A Report from the American Heart Association. Circulation 2016; 133(4): e38-e360. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000350>.
James PA, Oparil S, Carter BL et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507–520. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2013.284427>.
Egan BM, Zhao Y, Axon RN et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124(9): 1046–1058. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.111.030189>.
Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012; 380(9841): 601–610. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)60987–8>.
Paneni F, Diaz Canestro C, Libby P et al. The aging cardiovascular system: understanding it at the cellular and clinical levels. J Am Coll Cardiol 2017; 69(15):1952–1967. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2017.01.064>.
van Sloten TT, Sedaghat S, Laurent S et al. Carotid stiffness is associated with incident stroke: a systematic review and individual participant data meta-analysis. J Am Coll Cardiol 2015; 66(19): 2116–2125. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.08.888>.
Burt V, Whelton P, Rocella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25(3): 305–313. Dostupné z DOI: <http://dx.doi.org/10.1161/01.hyp.25.3.305>.
Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res 2015; 116(6): 976–990. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.116.303604>.
Taylor KS, Murai H, Millar PJ et al. Arousal from sleep and sympathetic excitation during wakefulness. Hypertension 2016; 68(6): 1467–1474. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.116.08212>.
Bibbins-Domingo K, Chertow GM, Coxson PG et al. Projected effect of dietary salt reductions on future cardiovascular disease: N Engl J Med 2010; 362(7): 590–599. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0907355>.
Ridker PM. From CRP to IL-6 to IL-1: moving upstream to identify novel targets for atheroprotection. Circ Res 2016; 118(1): 145–156. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.115.306656>.
Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24(6): 983–991. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjh.0000226182.60321.69>.
Preis SR, Hwang SJ, Coady S et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950–2005. Circulation 2009; 119(13): 1728–1785. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.108.829176>.
Gore MO, Patel MJ, Kosiborod M et al. Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994–2006, NRMI. Circ Cardiovasc Qual Outcomes 2012; 5(6): 791–797. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCOUTCOMES.112.965491>.
Standl E, Schnell O, McGuire DK. Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res 2016; 118(11):1830–1843. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.116.306924>.
Huxley RR, Filion KB, Konety S et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; 108(1): 56–62. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2011.03.004>.
Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009; 53(5 Suppl): S35-S42. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.09.055>.
Emdin CA, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313(6): 603–615. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.18574>.
Standards of medical care in diabetes – 2016: summary of revisions. Diabetes Care 2016; 39(Suppl 1): S4-S5. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16-S003>.
Adder AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): a prospective observational study. BMJ 2000; 321(7258): 412–423. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.321.7258.412>.
Cushman WC, Evans GW, Byington RP et al. ACCORD study group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17):1575–1585. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001286>.
Fox CS, Golden SH, Anderson C, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation 2015; 132(8): 691–718. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000230>.
Lathief S, Inzucchi SE. Approach to diabetes management in patients with CVD. Trends Cardiovasc Med 2016; 26(2):165–179. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tcm.2015.05.005>.